Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
Latest Information Update: 31 Mar 2023
At a glance
- Drugs Tisagenlecleucel (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 13 Dec 2022 Results assessing the frequency of CD19 loss in large B-cell lymphomas patients treated with tisa-cel and identified CD79 as an antigen highly expressed by immunohistochemistry (IHC) in CD19-negative biopsies. We then generated and optimized an anti-CD79 CART (CART79) and subsequently cloned a dual anti-CD79b/anti-CD19 CART that showed high potency against CD19-neg models, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 01 Oct 2020 Status changed from active, no longer recruiting to completed.
- 25 Jun 2020 Planned End Date changed from 1 Apr 2021 to 1 Jul 2021.